Fu, X; Wei, S; Wang, T; Fan, H; Zhang, Y; Da Costa, C; Brandner, S; ... Li, N; + view all Fu, X; Wei, S; Wang, T; Fan, H; Zhang, Y; Da Costa, C; Brandner, S; Yang, G; Pan, Y; He, Y; Li, N; - view fewer (2022) Research Status of the Orphan G Protein Coupled Receptor 158 and Future Perspectives. Cells , 11 (8) , Article 1334. 10.3390/cells11081334.

Preview

Text Brandner_cells-11-01334-v3.pdf - Published Version Download (3MB) | Preview

Abstract

G-protein-coupled receptors (GPCRs) remain one of the most successful targets for therapeutic drugs approved by the US Food and Drug Administration (FDA). Many novel orphan GPCRs have been identified by human genome sequencing and considered as putative targets for refractory diseases. Of note, a series of studies have been carried out involving GPCR 158 (or GPR158) since its identification in 2005, predominantly focusing on the characterization of its roles in the progression of cancer and mental illness. However, advances towards an in-depth understanding of the biological mechanism(s) involved for clinical application of GPR158 are lacking. In this paper, we clarify the origin of the GPR158 evolution in different species and summarize the relationship between GPR158 and different diseases towards potential drug target identification, through an analysis of the sequences and substructures of GPR158. Further, we discuss how recent studies set about unraveling the fundamental features and principles, followed by future perspectives and thoughts, which may lead to prospective therapies involving GPR158.

Download activity - last month

Export as XMLCSVJSON

Download activity - last 12 months

Export as XMLCSVJSON

Downloads by country - last 12 months

Export as XMLJSONCSV

Archive Staff Only

View Item